In Depth 27 Jun 2024
CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin?
Discover more about CRISPR-Cas13, including how it differs from CRISPR-Cas9 and what the technology can be used for.
In Depth
- Latest Posts
In Depth 27 Jun 2024
The 2024 drug approval list: Eight new treatments you should know about
In this article, we take a look at eight much-anticipated drugs that have been approved by regulators so far this year.
In Depth 26 Jun 2024
Biotech megadeals: Exploring the surge in $100M+ deals
Biotech and healtcare contributed to more than one out of three megadeals in 2024, find out the reasons behind it.
In Depth 24 Jun 2024
Troublesome acquisitions: when biotech M&A goes wrong
Dive deeper into the world of M&A, as we take a look at some of the most prominent failed acquisitions of the last decade.
In Depth 19 Jun 2024
MASH candidates make a splash after first drug approval
The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients.
In Depth 17 Jun 2024
Moving with the times: biopharma royalty deals on the rise
A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.
ADVERTISEMENT
ADVERTISEMENT
In Depth 10 Jun 2024
ASCO 2024: The latest advances in oncology clinical trials
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.
In Depth 6 Jun 2024
CRISPR: A promising path to treating blindness
Rigorous research, which has been going on for more than a decade now, suggests that CRISPR could treat genetic diseases including blindness.
In Depth 5 Jun 2024
Evolving standards of care: new treatments for cervical cancer
New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients.
In Depth 3 Jun 2024
The biggest private biotech investments in May 2024
The companies Uniquity Bio, AltruBio, and BridgeBio Oncology Therapeutics bagged the biggest private biotech investments in May 2024.
In Depth 30 May 2024
Covalent biologics: a new class of drugs on the horizon
The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic.
In Depth 23 May 2024
Is prime editing ready for prime time?
Prime editing, a more advanced version of CRISPR/Cas9 technology, has been greenlit by the FDA to begin the first-ever clinical trial for this technology.
ADVERTISEMENT
